Back to results
US 2025/0137995 A1Published application
In vitro quality screening of human corneal stromal stem cells for cell-based therapy of corneal scarring
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsHin-Fai YAM, Yiqin DU, Vishal JHANJI, Isabelle BILLIG, Jose Alain SAHEL, Deepinder K. DHALIWAL
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method of determining effectiveness of corneal stromal stem cell therapy through evaluation of stem cell markers, inflammation markers, and assessing a scarring index.
Claims17
A method of determining effectiveness of corneal stromal stem cell (CSSC) therapy, the method comprising:
- (a) obtaining a CSSC sample;
- (b) measuring expression of at least one stemness marker in the CSSC sample for stem cell stability (ΔCT);
- (c) creating a conditioned medium by culturing the CSSC sample until the cell culture medium contains the desired level of extracellular product;
- (d) introducing the CSSC sample conditioned medium into a cell-based model of inflammation;
- (e) measuring expression of at least one biomarker in the cell-based model (ΔCT);
- (f) determining a ratio of inflammation of the CSSC sample (RInflam), wherein the RInflam is based on the expression fold change of at least one biomarker in the cell-based model;
- and
- (g) determining a scarring index (SI) score of the CSSC sample, where the SI is based on the expression of at least one stemness marker in the CSSC in (c) and the expression of at least one biomarker in the cell-based model in (e), wherein an SI score is representative of the effectiveness of the CSSC sample for reduction of corneal scar formation in CSSC therapy.
5 more elements
A method of treating, reducing, or preventing corneal scarring in a subject in need thereof, the method comprising:
- (a) obtaining a corneal stromal stem cell (CSSC) sample;
- (b) determining a scarring index (SI) score of the CSSC sample, wherein an SI score is representative of the effectiveness of the CSSC sample as a therapy for treating, reducing or preventing of corneal scar formation in CSSC therapy;
- (c) formulating an anti-scarring therapy comprising the CSSC sample;
- and
- (d) administering a therapeutically effective amount of the anti-scarring therapy to a target corneal tissue in the subject.
2 more elements
Dependencies are inferred from the claim text.